文献速递流行病学与生物统计基础与转化研究

女性BRCA相关癌症的风险评估、遗传咨询和基因检测:美国预防服务工作组更新证据报告和系统综述

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2019-01-01

本系统综述更新2013年美国预防服务工作组关于女性BRCA1/2相关癌症风险评估、遗传咨询和基因检测获益与危害的证据。纳入103项研究(92,712例),未发现直接评估这些干预降低癌症发病和死亡效果的研究;风险评估工具有中高准确性,遗传咨询可减少乳腺癌担忧,他莫昔芬、雷洛昔芬和芳香化酶抑制剂与安慰剂相比降低侵袭性乳腺癌风险,乳房切除术与卵巢切除术与癌症风险降低相关。

要点

  • 未发现直接评估风险评估、遗传咨询和基因检测降低BRCA1/2相关癌症发病和死亡效果的研究。
  • 8种风险评估工具指导遗传咨询转诊具有中高准确性(AUC 0.68-0.96)。
  • 他莫昔芬、雷洛昔芬和芳香化酶抑制剂与安慰剂相比降低侵袭性乳腺癌风险,但结果非突变携带者特异性。

核心结论

  • 在未近期诊断BRCA1/2相关癌症的女性中,当前研究尚未直接评估风险评估、遗传咨询和基因检测降低癌症发病和死亡的获益与危害。

研究设计与样本

  • 系统综述更新2013年美国预防服务工作组证据报告,检索Cochrane图书馆、MEDLINE、PsycINFO、EMBASE(更新检索2013年1月1日至2019年3月6日;新关键问题及人群检索1994年1月1日至2019年3月6日)及参考文献列表。
  • 纳入鉴别准确性研究、随机临床试验(RCTs)和观察性研究,对象为未近期诊断BRCA1/2相关癌症的女性。
  • 共纳入103项研究(110篇文章;N=92,712);两名评价者独立评估研究质量。

主要发现

  • 14项研究(n=43,813)评估8种指导遗传咨询转诊的风险评估工具,显示中高准确性(受试者工作特征曲线下面积0.68-0.96)。
  • 28项研究(n=8,060)表明遗传咨询与乳腺癌担忧、焦虑和抑郁减少相关,风险理解增加,检测意愿降低。
  • 20项研究(n=4,322)显示检测后乳腺癌担忧和焦虑在阳性结果女性中较高、其他女性中较低;检测后风险理解较高。
  • 8项RCTs(n=54,651)中,他莫昔芬(相对风险[RR] 0.69 [95%CI, 0.59-0.84];4项试验)、雷洛昔芬(RR 0.44 [95%CI, 0.24-0.80];2项试验)和芳香化酶抑制剂(RR 0.45 [95%CI, 0.26-0.70];2项试验)与安慰剂相比与侵袭性乳腺癌风险降低相关;结果非突变携带者特异性。
  • 乳房切除术与乳腺癌发病率降低90%至100%相关(6项研究;n=2,546),与乳腺癌死亡率降低81%至100%相关(1项研究;n=639);卵巢切除术与卵巢癌降低69%至100%相关(2项研究;n=2,108);乳房切除术并发症常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未发现直接评估风险评估、遗传咨询和基因检测降低BRCA1/2相关癌症发病和死亡效果的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathogenic mutations in breast cancer susceptibility genes BRCA1 and BRCA2 increase risks for breast, ovarian, fallopian tube, and peritoneal cancer in women; interventions reduce risk in mutation carriers. OBJECTIVE: To update the 2013 US Preventive Services Task Force review on benefits and harms of risk assessment, genetic counseling, and genetic testing for BRCA1/2-related cancer in women. DATA SOURCES: Cochrane libraries; MEDLINE, PsycINFO, EMBASE (January 1, 2013, to March 6, 2019, for updates; January 1, 1994, to March 6, 2019, for new key questions and populations); reference lists. STUDY SELECTION: Discriminatory accuracy studies, randomized clinical trials (RCTs), and observational studies of women without recently diagnosed BRCA1/2-related cancer. DATA EXTRACTION AND SYNTHESIS: Data on study methods, setting, population characteristics, eligibility criteria, interventions, numbers enrolled and lost to follow-up, outcome ascertainment, and results were abstracted. Two reviewers independently assessed study quality. MAIN OUTCOMES AND MEASURES: Cancer incidence and mortality; discriminatory accuracy of risk assessment tools for BRCA1/2 mutations; benefits and harms of risk assessment, genetic counseling, genetic testing, and risk-reducing interventions. RESULTS: For this review, 103 studies (110 articles; N = 92 712) were included. No studies evaluated the effectiveness of risk assessment, genetic counseling, and genetic testing in reducing incidence and mortality of BRCA1/2-related cancer. Fourteen studies (n = 43 813) of 8 risk assessment tools to guide referrals to genetic counseling demonstrated moderate to high accuracy (area under the receiver operating characteristic curve, 0.68-0.96). Twenty-eight studies (n = 8060) indicated that genetic counseling was associated with reduced breast cancer worry, anxiety, and depression; increased understanding of risk; and decreased intention for testing. Twenty studies (n = 4322) showed that breast cancer worry and anxiety were higher after testing for women with positive results and lower for others; understanding of risk was higher after testing. In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; 2 trials), and aromatase inhibitors (RR, 0.45 [95% CI, 0.26-0.70]; 2 trials) were associated with lower risks of invasive breast cancer compared with placebo; results were not specific to mutation carriers. Mastectomy was associated with 90% to 100% reduction in breast cancer incidence (6 studies; n = 2546) and 81% to 100% reduction in breast cancer mortality (1 study; n = 639); oophorectomy was associated with 69% to 100% reduction in ovarian cancer (2 studies; n = 2108); complications were common with mastectomy. CONCLUSIONS AND RELEVANCE: Among women without recently diagnosed BRCA1/2-related cancer, the benefits and harms of risk assessment, genetic counseling, and genetic testing to reduce cancer incidence and mortality have not been directly evaluated by current research.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nelson HD, Pappas M, Cantor A, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31429902. doi:10.1001/jama.2019.8430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。